Novo Nordisk (NVO-2.98%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

Novo Nordisk NOVO.B-3.64%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors ...

Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ... Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills.

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, were looking for a way to tackle diabetes, which the wife suffered from.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...